Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
V3-Myoma
- Development stage
- Phase 2
- Lead developer
- Immunitor
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
V3-Myoma is an orally administered therapeutic vaccine developed as an immunostimulant for the treatment of uterine fibroids (myomas). Upon administration, it is designed to stimulate the immune system, specifically inducing a cytotoxic T-lymphocyte-mediated response against cells expressing myoma-associated antigens. This immune activation may reduce the growth of myomas and improve related symptoms. V3-Myoma is classified as both an inactivated vaccine and a therapeutic vaccine, with its mechanism of action based on general immunostimulation rather than targeting specific molecular pathways. The drug was initially developed by Immunitor and has been investigated in clinical trials for uterine fibroids[1][2].
- Other names
- oral myoma vaccine v3-myoma
Beyond the preview
Go deeper on V3-Myoma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on V3-Myoma.